NASDAQ:HOWL Werewolf Therapeutics (HOWL) Stock Price, News & Analysis $0.99 0.00 (0.00%) Closing price 10/30/2026 04:00 PM EasternExtended Trading$1.00 +0.01 (+1.00%) As of 06:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Werewolf Therapeutics Stock (NASDAQ:HOWL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Werewolf Therapeutics alerts:Sign Up Key Stats Today's Range$0.97▼$1.0950-Day Range$0.87▼$1.1052-Week Range$0.27▼$1.43Volume415,502 shsAverage Volume412,608 shsMarket Capitalization$47.92 millionP/E RatioN/ADividend YieldN/APrice Target$4.00Consensus RatingHold Company Overview Werewolf Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cancer treatments that stimulate the immune system. The company’s approach is designed to activate immune responses within the tumor microenvironment while limiting exposure to healthy tissues. Werewolf’s technology platform, known as INDUKINE, uses conditionally activated cytokines. These therapeutic proteins are intended to remain inactive in the bloodstream and become activated primarily in tumors, where they may help recruit and enhance immune cells to attack cancer. The company has developed investigational programs based on cytokines including interleukin-2, interleukin-12 and interleukin-18. The company’s pipeline has included WTX-124, an investigational, tumor-activated interleukin-2 therapy, and WTX-330, an investigational interleukin-12 program. These candidates have been evaluated in clinical studies for patients with advanced or metastatic solid tumors. Werewolf Therapeutics was founded in 2017 and is headquartered in Waltham, Massachusetts.AI Generated. May Contain Errors. Read More Werewolf Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreHOWL MarketRank™: 3.169023304525 of 5 starsWerewolf Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 407th out of 894 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingWerewolf Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 1 strong buy rating, 2 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialWerewolf Therapeutics has a consensus price target of $4.00, representing about 305.6% upside from its current price of $0.99.Amount of Analyst CoverageWerewolf Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Werewolf Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Werewolf Therapeutics are expected to grow in the coming year, from ($0.89) to ($0.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Werewolf Therapeutics is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Werewolf Therapeutics is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioWerewolf Therapeutics has a P/B Ratio of 1.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Werewolf Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.35% of the float of Werewolf Therapeutics has been sold short.Short Interest Ratio / Days to CoverWerewolf Therapeutics has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Werewolf Therapeutics has recently decreased by 6.18%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldWerewolf Therapeutics does not currently pay a dividend.Dividend GrowthWerewolf Therapeutics does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.36 News SentimentWerewolf Therapeutics has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Werewolf Therapeutics this week, compared to 5 articles on an average week.Search Interest1 people have searched for HOWL on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Werewolf Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Werewolf Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders23.60% of the stock of Werewolf Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions64.84% of the stock of Werewolf Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Werewolf Therapeutics' insider trading history. Receive HOWL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Werewolf Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HOWL Stock News HeadlinesWerewolf Therapeutics (HOWL) Set to Announce Earnings on Tuesday4 hours ago | americanbankingnews.comWerewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual MeetingOctober 30 at 10:28 AM | markets.businessinsider.comThe most dangerous moment in a financial crisisDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. Now, after 55 years of market analysis, he says conditions are forming for a financial crisis that could rival or exceed 2008.November 2 at 1:00 AM | Weiss Ratings (Ad)Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 2026 Annual MeetingOctober 30 at 8:30 AM | globenewswire.comWerewolf Therapeutics, Inc. (NASDAQ:HOWL) Stock Has Consensus Target Price of $4.00 According to BrokeragesOctober 30 at 3:29 AM | americanbankingnews.comCritical Review: Werewolf Therapeutics (NASDAQ:HOWL) & Oncocyte (NASDAQ:IMDX)October 28, 2026 | americanbankingnews.comBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX)September 24, 2026 | globenewswire.comBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)September 9, 2026 | globenewswire.comSee More Headlines HOWL Stock Analysis - Frequently Asked Questions How have HOWL shares performed this year? Werewolf Therapeutics' stock was trading at $0.6335 on January 1st, 2026. Since then, HOWL stock has increased by 55.7% and is now trading at $0.9861. How were Werewolf Therapeutics' earnings last quarter? Werewolf Therapeutics, Inc. (NASDAQ:HOWL) released its quarterly earnings results on Thursday, May, 7th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.04. When did Werewolf Therapeutics IPO? Werewolf Therapeutics (HOWL) raised $120 million in an initial public offering (IPO) on Wednesday, April 28th 2021. The company issued 7,500,000 shares at $15.00-$17.00 per share. Jefferies, SVB Leerink and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager. Who are Werewolf Therapeutics' major shareholders? Top institutional shareholders of Werewolf Therapeutics include Covestor Ltd (0.28%), Vontobel Holding Ltd. (0.12%) and Vilga Financial Planning LLC (0.11%). Insiders that own company stock include Bioventures 2014 LP Mpm, Ra Capital Management, LP and Luke Evnin. View institutional ownership trends. How do I buy shares of Werewolf Therapeutics? Shares of HOWL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Werewolf Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Werewolf Therapeutics investors own include Century Therapeutics (IPSC), Allogene Therapeutics (ALLO), Cabaletta Bio (CABA), Tenaya Therapeutics (TNYA), IonQ (IONQ), Caribou Biosciences (CRBU) and Janux Therapeutics (JANX). Company Calendar Last Earnings5/07/2026Today11/01/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 HOWL's financial health is in the Green zone, according to TradeSmith. HOWL has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:HOWL CIK1785530 Webwerewolftx.com Phone617-952-0555FaxN/AEmployees14Year Founded2017Price Target and Rating Average Price Target for Werewolf Therapeutics$4.00 High Price Target$7.00 Low Price Target$1.00 Potential Upside/Downside+305.6%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$60.82 million Net MarginsN/A Pretax Margin-164.82% Return on Equity-166.99% Return on Assets-59.88% Debt Debt-to-Equity RatioN/A Current Ratio2.91 Quick Ratio2.91 Sales & Book Value Annual Sales$1.88 million Price / Sales25.49 Cash FlowN/A Price / Cash FlowN/A Book Value$0.51 per share Price / Book1.93Miscellaneous Outstanding Shares48,600,000Free Float37,130,000Market Cap$47.92 million OptionableOptionable Beta0.55 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:HOWL) was last updated on 10/30/2026 by MarketBeat.com Staff. From Our PartnersI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredDoes your nest egg have an expiration date?A $250,000 nest egg growing at 5% a year and paying out $2,500 a month runs dry in just over a decade. Start w...Investors Alley | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredElon says the ‘S’ wordElon Musk and Sam Altman have sued each other and feuded for years. Yet within days of one another, both men d...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Werewolf Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Werewolf Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
